Use of adjunctive technologies in the treatment of patients with systemic sclerosis: a case series

Patients with systemic sclerosis (SSc) represent a heterogeneous and therapeutically challenging group. Disease progression is often associated not only with reduced quality of life but also with severe organ involvement. Despite advances in the use of biologic agents, treatment options for SSc remain limited.

Adjunctive treatment methods that target the peripheral vascular system may offer therapeutic benefit for this population. Enhanced external counterpulsation (EECP), which has shown efficacy in refractory angina, could also hold potential in systemic connective tissue diseases. Its positive impact on endothelial function suggests utility beyond cardiology in diseases where progressive microvascular remodeling and tissue hypoxia play key pathogenic roles.

This article presents a case series describing the initial experience of EECP use in 3 female patients with SSc as an adjunct to optimized pharmacological therapy.

1. Mamieva ZA, Lishuta AS, Belenkov YuN, et al. Possibilities of Enhanced External Counterpulsation Using in Clinical Practice. Ratsional'naya Farmakoterapiya v Kardiologii. 2017;13(2):238-247. (In Russ.).

2. Hui JCK, Lawson WE, Barsness GW. EECP in the treatment of endothelial dysfunction: preventing progression of cardiovascular disease. Journal of Geriatric Cardiology. 2010;7(2):79-87.

3. Bockeria LA, Bockeria OL, Glushko LA, et al. New opportunities, prospects and the expansion of clinical indications for the use of enhanced external counterpulsation. Byulleten' NTsSSKh im. A.N. Bakuleva RAMN. 2021; 22(2):119-29. (In Russ.).

4. Xu L, Cui M, Zhao W. The Effect of EECP on Ischemic Heart Failure: a Systematic Review. Curr Cardiol Rep. 2023 Oct;25(10):1291- 1298. doi: 10.1007/s11886-023-01943-1. Epub 2023 Aug 29.

5. Akhtar M, Wu G, Du Z, et al. Effect of External Counterpulsation on Plasma Nitric Oxide and Endothelin-1 Levels. Am J Cardiol. 2006 Jul 1;98(1):28-30. doi: 10.1016/j.amjcard. 2006.01.053. Epub 2006 May 3.

6. https://www.consultant.ru/document/cons_doc_LAW_384782/

7. Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. 1999 Jun;33(7):1833-40. doi: 10.1016/s0735-1097(99)00140-0.

8. Subramanian R, Nayar S, Meyyappan C, et al. Effect of Enhanced External Counter Pulsation Treatment on Aortic Blood Pressure, Arterial Stiffness and Ejection Fraction in Patients with Coronary Artery Disease. J Clin Diagn Res. 2016 Oct;10(10):OC30- OC34. doi: 10.7860/JCDR/2016/23122.8743. Epub 2016 Oct 1.

9. Sahebjami F, Madani FR, Komasi S, et al. Refractory angina frequencies during 7 weeks treatment by enhanced external counterpulsation in coronary artery disease patients with and without diabetes. Ann Card Anaesth. 2019 Jul-Sep;22(3):278-282. doi: 10.4103/aca.ACA_86_18.

10. Zhao M, Huang Y, Li L, et al. Enhanced External Counterpulsation Efficacy on Exercise Endurance in COPD Patients and Healthy Subjects: A Pilot Randomized Clinical Trial. Int J Chron Obstruct Pulmon Dis. 2020 Jan 7:15:25-31. doi: 10.2147/COPD.S225566. eCollection 2020.

11. Shilkina NP, Yunonin IE, Stolyarova SA, Vinogradov AA. Endothelial dysfunction and neurohumoral regulation of blood pressure in patients with systemic scleroderma. Nauchno-prakticheskaya revmatologiya. 2019;57(4): 445-451. (In Russ.).

12. Yin Q, Jiang H, Zhang Z, et al. Influence of enhanced external counterpulsation on endothelial function: a meta-analysis of randomized controlled trials. Scand Cardiovasc J. 2023 Dec;57(1):2273223. doi: 10.1080/14017431.2023.2273223. Epub 2023 Oct 24.

13. Romanowska-Prуchnicka K, Dziewit M, Lesiak A, et al. Scleroderma and sclerodermalike syndromes. Front Immunol. 2024 Jun 3:15:1351675. doi: 10.3389/fimmu.2024.1351675. eCollection 2024.

14. Wang Q, Hao J, Jiang W, Tan Q. Enhanced external counterpulsation increases coronary flow reserve in coronary microvascular disease. Saudi Med J. 2023 Dec;44(12): 1277-1282. doi: 10.15537/smj.2023.44.12.20230427.

15. Qin X, Deng Y, Wu D, et al. Does Enhanced External Counterpulsation (EECP) Significantly Affect Myocardial Perfusion? A Systematic Review & Meta-Analysis. PLoS One. 2016 Apr 5;11(4):e0151822. doi: 10.1371/journal.pone.0151822. eCollection 2016.

16. Singh V, Kumari G, Chhajer B, et al. Enhanced external counterpulsation effectiveness on clinical parameters in diabetic and non-diabetic coronary heart disease patients. Asian Journal of Pharmaceutical and Clinical Research. 2018;11(7):151-157. doi: 10.22159/ajpcr.2018.v11i7.25219.

17. Nagendra L, Dutta D, Sharma M, Bg H. Impact of Enhanced External Counter-pulsation Therapy on Glycaemic Control in People With Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. TouchREV Endocrinol. 2023 Nov;19(2):9-15. doi: 10.17925/EE.2023.19.2.8. Epub 2023 Oct 2.

18. Buschmann EE, Brix M, Li L, et al. Adaptation of external counterpulsation based on individual shear rate therapy improves endothelial function and claudication distance in peripheral artery disease. Vasa. 2016;45(4): 317-24. doi: 10.1024/0301-1526/a000544.

19. Zhang Y, Zhang Y, Wang Y, et al. Effects of Enhanced External Counterpulsation With Different Sequential Levels on Lower Extremity Hemodynamics. Front Cardiovasc Med. 2021 Dec 24:8:795697. doi: 10.3389/fcvm.2021.795697. eCollection 2021.

20. Munteanu A, Kundnani NR, Caraba A. Nailfold capillaroscopy abnormalities and pulmonary hypertension in mixed connective tissue disease and systemic sclerosis patients. Eur Rev Med Pharmacol Sci. 2024 Feb;28(4): 1314-1326. doi: 10.26355/eurrev_202402_35453.

21. Buschmann EE, Hillmeister P, Bondke Persson A, et al. Short-term external counterpulsation augments cerebral blood flow and tissue oxygenation in chronic cerebrovascular occlusive disease. Eur J Neurol. 2018 Nov; 25(11):1326-1332. doi: 10.1111/ene.13725.